MedTrace Logo

KSH01-R02-101 Solid Tumors

NCT05580796 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-04-03

No results posted yet for this study

Summary

1. . safety and tolerance
2. . objective response rate

Conditions

Interventions

DRUG

KSH01 injection

TCR-T cell injection

Sponsors & Collaborators

  • TCRx Therapeutics Co.Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-11
Primary Completion
2025-10-11
Completion
2027-10-11

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05580796 on ClinicalTrials.gov